Table 2.

Examination Program of the Sub-Sero Study.

		PATIENTS (N=40)
		Clinical	Imaging
Baseline	Week 0	SCAN interview Cognition Blood, ECG, BMI PANSS, BNSS, CDSSSWN, UKU, BOCS, EHI, CGIPSP, GAF, QLS, CSFQ	PET, [¹¹C]Cimbi-36 MRS sMRI/DTI
Treatment
	Week 1	Pimavanserin (34 mg/day)PANSS, ECG Blood, weight BNSS, CDSS SWN, UKU, BOCS, PSP
	Week 2	PANSS, ECG Blood, weight BNSS, CDSS SWN, UKU, BOCS, PSP	–
	Week 4	PANSS, ECG Blood, weight BNSS, CDSS SWN, UKU, BOCS, PSP	–
	Week 6	Cognition Blood, ECG, BMI PANSS, BNSS, CDSSSWN, UKU, BOCS, PSP, GAF, QLS, CGI, CSFQ	MRS sMRI/DTI
Wash out	Week 8	Blood, ECG PANSS	–

SCAN, Schedules for clinical assessment in neuropsychiatry; PANSS, Positive and negative syndrome scale; BNSS, Brief Negative Symptom Scale; BNSS, Calgary depression scale for schizophrenia; BOCS, The Brief Obsessive Compulsive Scale; SWN, Subjective well-being under neuroleptic treatment scale; UKU (measurement of side-effects), Udvalg for Kliniske Undersøgelser; PSP, Personal and Social Performance Scale; EHI, Edinburgh Handedness Inventory; BMI, Body Mass Index; QLS, Quality of Life Scale; CSFQ, Changes in Sexual Functioning Questionnaire; MRS, Magnetic resonance spectroscopy; sMRI, structural Magnetic Resonance Imaging; DTI, Diffusion Tensor Imaging.